<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04831281</url>
  </required_header>
  <id_info>
    <org_study_id>ATH-1017-PD-0201</org_study_id>
    <nct_id>NCT04831281</nct_id>
  </id_info>
  <brief_title>ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Athira Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Athira Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety and treatment effects of ATH-1017 in subjects&#xD;
      with Parkinson's Disease Dementia or Dementia with Lewy Bodies, with a randomized treatment&#xD;
      duration of 26 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed to evaluate the safety and treatment effects of ATH-1017 in subjects&#xD;
      with Parkinson's Disease Dementia or Dementia with Lewy Bodies, with a randomized,&#xD;
      double-blind, placebo-controlled, parallel-arm treatment duration of 26 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall treatment effect of ATH-1017 as reflected by the Global Statistical Test</measure>
    <time_frame>Week 26</time_frame>
    <description>The Global Statistical Test (GST) combines the scores from cognition and change in event-related potential (ERP) P300 latency</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event-Related Potential</measure>
    <time_frame>Week 2, 12, 26</time_frame>
    <description>Event-related potential (ERP) P300 latency change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognition</measure>
    <time_frame>Week 2, 12, 20, and 26</time_frame>
    <description>Alzheimer's Disease Assessment Scale-Cognitive Subscale [ADAS-Cog13] change from baseline (Range of 0 to 85, where 0 is least impairment and 85 is most severe impairment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Change</measure>
    <time_frame>Week 12 and 26</time_frame>
    <description>Clinical Global Impression of Change (CGI-C) change from baseline (Range of 1 to 7, where 1 is marked improvement and 7 is marked worsening)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activities of Daily Living</measure>
    <time_frame>Week 12 and 26</time_frame>
    <description>Alzheimer's Disease Cooperative Study - Activities of Daily Living, 23-item version [ADCS-ADL23] change from baseline (Range of 0 to 78, where a higher score indicates greater function)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Parkinson Disease Dementia</condition>
  <condition>Dementia With Lewy Bodies</condition>
  <arm_group>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily subcutaneous injection of Low Dose ATH-1017</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily subcutaneous injection of High Dose ATH-1017</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily subcutaneous injection of Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATH-1017</intervention_name>
    <description>Daily subcutaneous injection of ATH-1017 in a pre-filled syringe</description>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_label>Low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Daily subcutaneous injection of Placebo in a pre-filled syringe</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with confirmed diagnosis of Parkinson's disease or Dementia with Lewy Bodies&#xD;
&#xD;
          -  MoCA score 11 to 23, inclusive, at screening&#xD;
&#xD;
          -  Probable Parkinson's Disease Dementia or Lewy Body Dementia&#xD;
&#xD;
          -  BMI between ≥ 16and ≤ 35 kg/m2 for females and between≥ 18 and ≤ 35 kg/m2 for males at&#xD;
             Screening&#xD;
&#xD;
          -  Reliable and capable support person/caregiver, who is willing to accept responsibility&#xD;
             for supervising the treatment or, if required, administering study drug, and assessing&#xD;
             the condition of the subject throughout the study in accordance with all protocol&#xD;
             requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hoehn-Yahr stage 5&#xD;
&#xD;
          -  History of significant neurological disease other than PDD or DLB that may affect&#xD;
             cognition at onset of dementia&#xD;
&#xD;
          -  Subjects on deep brain stimulation&#xD;
&#xD;
          -  History of brain MRI scan indicative of any other significant abnormality&#xD;
&#xD;
          -  History of unexplained loss of consciousness, and epileptic fits&#xD;
&#xD;
          -  Hearing test result considered unacceptable for auditory ERP P300 assessment&#xD;
&#xD;
          -  Diagnosis of severe major depressive disorder even without psychotic features (GDS&#xD;
             score [15-item scale] &gt;7 at Screening)&#xD;
&#xD;
          -  Significant suicide risk based on C-SSRS&#xD;
&#xD;
          -  Significant psychosis (according to Diagnostic and Statistical Manual of Mental&#xD;
             Disorders)&#xD;
&#xD;
          -  Moderate or severe substance abuse disorder (according to DSM-5)&#xD;
&#xD;
          -  Myocardial infarction or unstable angina within the last 6 months&#xD;
&#xD;
          -  Clinically significant cardiac arrhythmia (including atrial fibrillation),&#xD;
             cardiomyopathy, or cardiac conduction defect (note: pacemaker is acceptable)&#xD;
&#xD;
          -  Clinically significant ECG abnormality at Screening&#xD;
&#xD;
          -  Chronic kidney disease (eGFR &lt; 45 mL/min using Cockcroft and Gault formula)&#xD;
&#xD;
          -  Hepatic impairment with alanine aminotransferase or aspartate aminotransferase &gt; 2&#xD;
             times the upper limit of normal, or Child-Pugh class B and C&#xD;
&#xD;
          -  Malignant tumor within 3 years before Screening&#xD;
&#xD;
          -  Memantine at any dose or combination&#xD;
&#xD;
          -  Donepezil at 23 mg&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xue Hua, Ph.D.</last_name>
    <phone>(425) 620-8501</phone>
    <email>clinicaltrials@athira.com</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 1, 2021</study_first_submitted>
  <study_first_submitted_qc>April 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's Disease Dementia</keyword>
  <keyword>Dementia with Lewy Bodies</keyword>
  <keyword>Dementia</keyword>
  <keyword>HGF/MET</keyword>
  <keyword>Hepatocyte Growth Factor</keyword>
  <keyword>Neurotrophic</keyword>
  <keyword>ATH-1017</keyword>
  <keyword>Event-Related Potential</keyword>
  <keyword>ERP P300</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Lewy Body Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

